AURELIA ONLINE / 7.5mgから5mgへ戻す
When Should Mounjaro Be Reduced from 7.5 mg Back to 5 mg?
Reasons to reduce from Mounjaro 7.5 mg to 5 mg, expected changes, monitoring, and how dose reduction differs from stopping treatment.
Key points
- Persistent gastrointestinal adverse effects.
- Difficulty eating or drinking, dehydration, weakness, or excessively rapid weight loss.
- The target weight has been reached and 5 mg previously provided adequate control.
Common reasons to step down
- Persistent gastrointestinal adverse effects.
- Difficulty eating or drinking, dehydration, weakness, or excessively rapid weight loss.
- The target weight has been reached and 5 mg previously provided adequate control.
What may change after returning to 5 mg
- Appetite suppression may become weaker, but adverse effects may improve.
- Weight should be monitored over several weeks rather than judged after one injection.
- Returning to 5 mg is not the same as stopping treatment.
Monitoring
- Track weekly weight, appetite, waist circumference, bowel movements, hydration, and blood glucose when applicable.
- Contact the clinician earlier if weight rises rapidly or glucose control worsens.
Frequently asked questions
Common reasons to step down?
Persistent gastrointestinal adverse effects. Difficulty eating or drinking, dehydration, weakness, or excessively rapid weight loss. The target weight has been reached and 5 mg previously provided adequate control.
What may change after returning to 5 mg?
Appetite suppression may become weaker, but adverse effects may improve. Weight should be monitored over several weeks rather than judged after one injection. Returning to 5 mg is not the same as stopping treatment.
Monitoring?
Track weekly weight, appetite, waist circumference, bowel movements, hydration, and blood glucose when applicable. Contact the clinician earlier if weight rises rapidly or glucose control worsens.
References
Related pages
Book an online consultationThis page provides general medical information and does not replace individual diagnosis or treatment. In Japan, Mounjaro is approved for type 2 diabetes; use for weight management is off-label. Dose changes must be decided after medical review.